Kopran share news, announcements and annual reports
NSE: KOPRANBSE: 524280Pharmaceuticals & BiotechnologySmall Cap
Kopran Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 1993 on BSE, Jun 1999 on NSE
Last close ₹239.05down ₹12.95 (5.14%)BSE ₹239.30
Share price at the NSE close on 30 Oct 2026. Previous close ₹252.00.
30 Oct: open ₹253.80, high ₹253.80, low ₹237.50
52-week range of traded prices to 30 Oct 2026
₹107.00Low, 30 Mar 2026₹295.83High, 30 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,155 Cr1,663rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 46.24
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.18
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.26%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 4.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.29
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,52,24248.4% delivered
Kopran board and management
22 filed, newest first.
Jun 2026
May 2026
Mar 2026
Sep 2025
18 Sep · Management
May 2024
16 May · Management
May 2019
8 May · Management
Apr 2019
25 Apr · Management
Sep 2016
Apr 2016
Aug 2013
12 Aug · Management
Mr. V. N. Khanna, Independent Director of the Company was appointed as new Chairman of the Board of Directors.
Feb 2013
13 Feb · Management
Board of Directors of the Company at its meeting held on February 12, 2013 has approved the following: (1) Appointment of Mr. V. K. Bhandari as an Independent Director of the Company with effect from February 12, 2013. (2) Renewal of the appointment of Mr. Ajit Jain as Whole Time Director of the Company for further period of 3 years w.e.f February 01, 2013.
Jul 2012
16 Jul · Management
Dr. Suresh K. Parikh, Non Executive Independent Director of the Company has resigned with effect from July 13, 2012 and Board has accepted his resignation in its Board Meeting held on July 13, 2012. Mr. Amit Rajan has been appointed as an additional Director in the same Board Meeting.
Feb 2011
17 Feb · Management
Board of Director have approved the appointment of Mr. Abhinav Mathur as a Company Secretary & Compliance Officer of the Company with effect from December 27, 2010 at their Board Meeting held on February 11, 2011.
Jan 2010
29 Jan · Management
Kopran Ltd. has informed the Exchange that the Company has appointed Mr. Ajit Jain, Chief Operating Officer (COO) as Director & COO of the Company with effect from February 01, 2010.
Nov 2009
4 Nov · Management
Kopran Ltd. has informed the Exchange vide notes to Accounts in the Un-audited Financial Results for the quarter ended September 30, 2009 (taken on record by the Board of Directors of the Company at its meeting held on October 31, 2009) regarding Auditors Observation and Management Comments : "(a) Investments & Advances made to Subsidiary Company, Kopran Research Laboratories Ltd amounting to Rs.6963.95 Lacs are in the opinion of the Auditors doubtful of realisation. In the opinion of the Management since the investment in the Subsidiary Company, Kopran Research Laboratories Ltd is long term for strategic reasons, no provision is required to be made; b) Balances of some of the Debtors, Creditors, Loans & Advances are subject to confirmation, reconciliation and consequent adjustment, if any. However, in the opinion of the management such adjustments, if any, will not be material".
Jul 2009
29 Jul · Management
Kopran Ltd. has informed the Exchange vide notes to Accounts in the Un- audited Financial Results for the quarter ended June 30, 2009 (taken on record by the Board of Directors of the Company at its meeting held on July 29, 2009) regarding Auditors Observation :"(a)Investments and Advances made to Subsidiary Company, Kopran Research Laboratories Ltd amounting to Rs. 6952.26 Lacs, are in the opinion of the Auditors doubtful of realisation. In the opinion of the Management since the investment in the Subsidiary Company, Kopran Research Laboratories Ltd is long term for strategic reason , no provision is required to be made. b) Balances of some of the Debtors, Creditors, Loans & Advances are subject to confirmation, reconciliation and consequent adjustment, if any. However, in the opinion of the management such adjustments, if any, will not be material".
Oct 2008
27 Oct · Management
Kopran Ltd. has informed the Exchange vide notes to Accounts in the Unaudited Financial Results for the quarter ended September 30, 2008 (taken on record by the Board of Directors of the Company at its meeting held on October 25, 2008) regarding Auditor's observation: "(a) Investments and Advances made to Subsidiary Company, Kopran Research Laboratories Ltd amounting to Rs. 6413.07 Lacs are in the opinion of the Auditors doubtful of realisation. In the opinion of the Management since the investment in the Subsidiary Company, Kopran Research Laboratories Ltd is long term for strategic reasons and is proposed to be merged with the Company, no provision is required to be made. (b) Balances of some of the Debtors, Creditors, Loans & Advances are subject to confirmation, reconciliation and consequent adjustment, if any. However, in the opinion of the management such adjustments, if any, will not be material".
Aug 2008
7 Aug · Management
Kopran Ltd. has informed the Exchange vide notes to Accounts in the Unaudited Financial Results for the quarter ended June 30, 2008 (taken on record by the Board of Directors of the Company at its meeting held on July 30, 2008) regarding Auditor's observation: "(a) Investments and Advances made to Subsidiary Company, Kopran Research Laboratories Ltd amounting to Rs. 6418.51 Lacs in the opinion of the Auditors are doubtful of realisation. In the opinion of the Management since the Subsidiary Company, Kopran Research Laboratories Ltd is long term for strategic reasons and is proposed to be merged with the Company hence no provision is required to be made. (b) Balances of some of the Debtors, Creditors, Loans & Advances are subject to confirmation, reconciliation and consequent adjustment, if any. However, in the opinion of the management such adjustments, if any, will not be material".
Jul 2008
2 Jul · Management
Kopran Ltd. has informed the Exchange vide notes to Accounts in the Audited Financial Results for the period ended March 31, 2008 (taken on record by the Board of Directors of the Company at its meeting held on June 30, 2008) that: "Investments and Advances made to Subsidiary Company, Kopran Research Laboratories Ltd amounting to Rs. 6417.70 Lacs in the opinion of the Auditors are doubtful of realisation. In the opinion of the Management since the Subsidiary Company, Kopran Research Laboratories Ltd is long term for strategic reason and is proposed to be merged with the Company hence no provision is required to be made".
Jan 2008
11 Jan · Management
Kopran Ltd. has informed the Exchange regarding auditors observation vide notes to Accounts in the audited Financial Results for the period ended September 30, 2007 that : "Investments and Advances made to Subsidiary Company, Kopran Research Laboratories Ltd amounting to Rs. 6504.77 Lacs and Joint Venture, Golbalpharma Co. LLC amounting to Rs. 1196.56 Lacs which in the opinion of the Auditors are doubtful. In the opinion of the Management since the Subsidiary Company, Kopran Research Laboratories Ltd is Proposed to be merged and investments in Joint Venture, Global Pharma Co. LLC are made for long term period hence no provision is required to be made".
Jul 2007
2 Jul · Management
Kopran Ltd. has informed the Exchange that : "(1) Investments and Advances made to Subsidiary Company, Kopran Research Laboratory Ltd amounting to Rs. 6555.57 Lacs and Joint Venture, Golbalpharma Co. LLC amounting to Rs. 1193.84 Lacs which in the opinion of the Auditors are doubtful. In the opinion of the Management since the Subsidiary Company, Kopran Research Laboratory Ltd is proposed to be merged and investments in Joint Venture, Golbalpharma Co. LLC are made for long term period hence no provision is required to be made. (2) Recognition of Export benefit under Target Plus Incentive Scheme proposed by the Govt. of Rs. 320 Lacs in earlier years, where later on export benefit under this scheme has been reduced retrospectively as per notification issued by the Govt. for which no provision has been made. In the opinion of the Management since this matter is pending before the Court hence no provision has been made".
Feb 2007
5 Feb · Management
Kopran Ltd. has informed the Exchange that "The resignation of Mr. Sumeet S. Maheshwari, Company Secretary of the Company has been accepted by the Board of Directors of the Company in their meeting held on 31st January, 2007. Mr. Surendra Somani, Executive Vice Chairman is the Compliance Officer of the Company at present."